Gene
SYK
SYK is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (11), Actionable biomarkers (2), Trial mentions (47), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SYK. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 10 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 30 of 11,460 | 0.26% |
| 2022 | 0 of 8,285 | 0.00% | 24 of 13,598 | 0.18% |
| 2021 | 1 of 8,692 | 0.01% | 33 of 15,045 | 0.22% |
| 2020 | 4 of 7,640 | 0.05% | 32 of 14,459 | 0.22% |
| 2019 | 7 of 7,300 | 0.10% | 23 of 12,159 | 0.19% |
| 2018 | 6 of 6,927 | 0.09% | 19 of 11,854 | 0.16% |
| 2017 | 7 of 6,558 | 0.11% | 14 of 11,595 | 0.12% |
Showing 10 of 37 years.
Assay-provider ledger (11)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Inception IBD Inc. | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | November 04, 2020 |
| Invitrogen | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | November 04, 2020 |
| Matrix Science | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | November 04, 2020 |
| Thermo Scientific | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | November 04, 2020 |
| Sanway Gene Technology Inc. | Unclassified | No clinical or analytical validation recorded for this pair | 1 | November 01, 2016 |
Showing 5 of 11 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SYK amplification | Syk Inhibitors | response-associated | Mantle cell lymphoma | Cancer Genome Interpreter |
| SYK amplification | Syk Inhibitors | response-associated | chronic lymphocytic leukemia | Cancer Genome Interpreter |
Trial mentions (47)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02568683 | Trial eligibility (AACT) |
| NCT06233110 | Trial eligibility (AACT) |
| NCT01994382 | Trial eligibility (AACT) |
| NCT03742258 | Trial eligibility (AACT) |
| NCT03139981 | Trial eligibility (AACT) |
Showing 5 of 47 trial mentions.
Target-disease associations (608)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of limbs | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acute hepatic failure | phenotype | Expression Atlas |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 608 associations.
Vendor sourcing (164)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Missense changes are a common disease-causing mechanism. Therefore, this variant is classified as u... | View ClinVar record SCV002521629.1 |
| AbbVie Inc. | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Subject has previous exposure to any systemic biologic therapy (e.g., etanercept, adalimumab, rituximab, abatacept, tocilizumab), to Janus kinase (JAK)... | View trial NCT01999192 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | SYK | View trial NCT01999192 |
| Acerta Pharma BV (Netherlands) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subjec... | View trial NCT02180724 |
| Acerta Pharma BV (Netherlands) | Trial sponsor | Mentioned in trial textTrial free-text mention | SYK | View trial NCT02180724 |
Showing 5 of 164 sourcing records.
Trial-cited literature (303)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Effectiveness and Safety of a Supplement Containing a Pharmacologically Active Basidiomycete Mushroom for Chronic Fatigue and Post-COVID-19 Fatigue Syndrome: Protocol for a Randomized Controlled Trial. | JMIR research protocols | 2026 | 0 |
| Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response. | Antioxidants & redox signaling | 2025 | 8 |
| Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. | The Lancet. Haematology | 2025 | 8 |
| Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. | Cancer research communications | 2025 | 4 |
| Multidrug-Resistant Sepsis: A Critical Healthcare Challenge. | Antibiotics (Basel, Switzerland) | 2024 | 100 |
Showing 5 of 303 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A353T | 1 | 2015 | PMID 25741868 |
| p.M450I | 1 | 2015 | PMID 25741868 |
| p.P342T | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (56)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Oxygen | Chemical | associate |
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. | 2021 |
| INFLIXIMAB | Chemical | associate |
The FcγRIIa-Syk Axis Controls Human Dendritic Cell Activation and T Cell Response Induced by Infliximab Aggregates. | 2020 |
| METFORMIN | Chemical | positive_correlate |
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. | 2017 |
| Anemia, Hemolytic, Autoimmune | Disease | associate |
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. | 2025 |
| Leukemia, Myeloid, Acute | Disease | associate |
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. | 2025 |
Showing 5 of 56 relation assertions.
Organizations publishing (321)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 26 | 2010 to 2023 |
| Harvard Medical School | Academic | 11 | 2006 to 2023 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Academic | 8 | 2021 to 2025 |
| Dana-Farber Cancer Institute | Other | 8 | 2014 to 2021 |
| Stanford University | Academic | 7 | 2011 to 2021 |
Showing 5 of 321 organizations.
Where SYK appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
556 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.